Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Claire M Nolan (London, United Kingdom), Claire M. Nolan, Matthew Maddocks, Jane L. Canavan, Sarah E. Jones, Samantha S.C. Kon, Athol U. Wells, David M. Hansell, Joseph Jacobs, Paul Cullinan, Toby M. Maher, William D.-C. Man. The reliability and validity of the 4 metre gait speed (4MGS) in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 1572

Member's Comments

No comment yet.

Related content which might interest you: Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF: clinical aspects Year: 2015 A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Test-retest reliability for the 30-meter walk test (30mWT) in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - Exercise training: new groups, new methods and outcomes Year: 2010 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity Year: 2013 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Is there a relationship between quality of life and exercise performance in idiopathic pulmonary fibrosis (IPF)? Source: Eur Respir J 2007; 30: Suppl. 51, 577s Year: 2007 6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 96-103 Year: 2005 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012